Marco Colleoni
European Institute of Oncology · European Institute of Oncology, Milan, Italy
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marco Colleoni as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04304352 · Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer PatientsEuropean Institute of Oncology · unknown · Advanced Breast Cancer · principal investigator
- Ph2NCT02005887 · TRial on the Endocrine Activity of Neoadjuvant DegarelixETOP IBCSG Partners Foundation · completed · Breast Cancer Invasive Nos · study chair
- Ph3NCT00553410 · Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast CancerETOP IBCSG Partners Foundation · completed · Breast Cancer · study chair
- Ph3NCT00022516 · Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast CancerETOP IBCSG Partners Foundation · completed · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:23 UTC. The ranking covers the 200 most relevant of 169 PubMed records, and a shared surname and initials can bring in a namesake. All 169 on PubMed
- 1,471 citationsRCR 45.8
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med · 20181,016 citationsRCR 33.5
- Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.Lancet Oncol · 2013959 citationsRCR 30.7
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.Lancet Oncol · 2018834 citationsRCR 27.8
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.N Engl J Med · 2019780 citationsRCR 28.5
- 715 citationsRCR 17.7
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.N Engl J Med · 2014578 citationsRCR 16.9
- Adjuvant ovarian suppression in premenopausal breast cancer.N Engl J Med · 2015541 citationsRCR 16.8
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.N Engl J Med · 2018529 citationsRCR 20.2
- 450 citationsRCR 17.6